Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AFL NASDAQ:LGN NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFLAflac$123.26+1.1%$116.91$96.95▼$124.00$62.73B0.612.40 million shs1.53 million shsLGNLGN$68.33-7.2%$84.95$26.96▼$107.24$7.38BN/A1.48 million shs1.47 million shsLGNDLigand Pharmaceuticals$309.25-2.2%$256.11$120.68▼$326.63$6.20B1.1275,466 shs245,665 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFLAflac0.00%+1.03%+3.76%+8.80%+20.10%LGNLGN0.00%-2.86%-14.35%+12.66%+7,365,999,900.00%LGNDLigand Pharmaceuticals0.00%-1.04%+23.75%+48.16%+159.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFLAflac$123.26+1.1%$116.91$96.95▼$124.00$62.73B0.612.40 million shs1.53 million shsLGNLGN$68.33-7.2%$84.95$26.96▼$107.24$7.38BN/A1.48 million shs1.47 million shsLGNDLigand Pharmaceuticals$309.25-2.2%$256.11$120.68▼$326.63$6.20B1.1275,466 shs245,665 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFLAflac0.00%+1.03%+3.76%+8.80%+20.10%LGNLGN0.00%-2.86%-14.35%+12.66%+7,365,999,900.00%LGNDLigand Pharmaceuticals0.00%-1.04%+23.75%+48.16%+159.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFLAflac 2.23Hold$114.50-7.10% DownsideLGNLGN 2.75Moderate Buy$93.1036.25% UpsideLGNDLigand Pharmaceuticals 2.88Moderate Buy$292.86-5.30% DownsideCurrent Analyst Ratings BreakdownLatest AFL, LGN, and LGND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026AFLAflac Keefe, Bruyette & WoodsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$115.00 ➝ $120.007/10/2026AFLAflac Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$100.00 ➝ $108.007/10/2026LGNLGN GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$106.00 ➝ $115.007/9/2026AFLAflac MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$112.007/9/2026AFLAflac Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$111.00 ➝ $120.007/9/2026LGNDLigand Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$266.00 ➝ $388.007/8/2026AFLAflac UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$114.00 ➝ $124.007/8/2026LGNDLigand Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$255.00 ➝ $332.007/7/2026AFLAflac Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (A-) ➝ Buy (B+)7/7/2026AFLAflac BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetUnderweight$99.00 ➝ $98.006/26/2026LGNLGN Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFLAflac$17.16B3.65$9.42 per share13.09$56.27 per share2.19LGNLGN$3.08B2.39$0.58 per share118.58$7.49 per share9.12LGNDLigand Pharmaceuticals$268.09M23.12$7.68 per share40.28$51.68 per share5.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFLAflac$3.65B$8.8113.9916.072.1425.60%13.88%3.34%8/6/2026 (Estimated)LGNLGN-$59.78M$0.23297.0941.66N/AN/AN/AN/AN/ALGNDLigand Pharmaceuticals$124.45M$7.3741.9635.223.1355.95%16.19%11.13%8/6/2026 (Estimated)Latest AFL, LGN, and LGND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026AFLAflac$1.78N/AN/AN/A$4.11 billionN/A8/6/2026Q2 2026LGNDLigand Pharmaceuticals$1.93N/AN/AN/A$62.32 millionN/A5/14/2026Q1 2026LGNLGN$0.19$0.13-$0.06$0.13N/A$1.04 billion5/7/2026Q1 2026LGNDLigand Pharmaceuticals$1.84$1.63-$0.21-$0.67$59.10 million$51.72 million4/29/2026Q1 2026AFLAflac$1.80$1.75-$0.05$1.98$4.20 billion$4.24 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAFLAflac$2.442.00%+15.68%27.70%44 YearsLGNLGNN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ALatest AFL, LGN, and LGND DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/27/2026AFLAflacquarterly$0.612.08%5/20/20265/20/20266/1/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFLAflac0.260.110.11LGNLGN1.061.301.30LGNDLigand Pharmaceuticals0.4521.2820.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFLAflac67.44%LGNLGNN/ALGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipAFLAflac0.80%LGNLGN0.01%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFLAflac12,716508.98 million504.91 millionOptionableLGNLGN7,000108.04 million108.03 millionN/ALGNDLigand Pharmaceuticals8020.04 million18.64 millionOptionableAFL, LGN, and LGND HeadlinesRecent News About These Companies3 Overlooked Stocks Positioned for the Next Market Rotation (LGND)...July 13 at 8:35 AM | marketbeat.comLigand Pharmaceuticals Incorporated $LGND is Villere ST Denis J & Co. LLC's 2nd Largest PositionJuly 11 at 10:55 AM | marketbeat.comSG Americas Securities LLC Sells 9,401 Shares of Ligand Pharmaceuticals Incorporated $LGNDJuly 11 at 9:27 AM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Mesoblast Limited (OtherMEOBF) and Cogstate Ltd (OtherCOGZF)July 9, 2026 | theglobeandmail.comLigand Pharmaceuticals (NASDAQ:LGND) Given New $388.00 Price Target at Bank of AmericaJuly 9, 2026 | marketbeat.comGranite Investment Partners LLC Decreases Holdings in Ligand Pharmaceuticals Incorporated $LGNDJuly 9, 2026 | marketbeat.comStifel Nicolaus Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock PriceJuly 9, 2026 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $332.00 at Stifel NicolausJuly 8, 2026 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 SharesJuly 7, 2026 | insidertrades.comInsider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells 5,000 Shares of StockJuly 6, 2026 | marketbeat.comMoran Wealth Management LLC Invests $3.85 Million in Ligand Pharmaceuticals Incorporated $LGNDJuly 6, 2026 | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Shares Sold by Stephens Investment Management Group LLCJuly 5, 2026 | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Shares Sold by Pictet Asset Management Holding SAJuly 3, 2026 | marketbeat.comLouisiana State Employees Retirement System Invests $1.74 Million in Ligand Pharmaceuticals Incorporated $LGNDJuly 2, 2026 | marketbeat.comLigand Pharmaceuticals: The Bull Case Is A Biotech ARM, The Bear Case Is Just Another Royalty TrustJune 30, 2026 | seekingalpha.comLigand Pharmaceuticals (NASDAQ:LGND) Hits New 1-Year High - Here's WhyJune 30, 2026 | marketbeat.comLigand Announces Closing of Convertible Senior Notes OfferingJune 25, 2026 | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Hits New 12-Month High - Still a Buy?June 24, 2026 | marketbeat.comLigand Pharmaceuticals Rises After Upsized Convertible Notes Pricing and Buyback PlanJune 23, 2026 | quiverquant.comQLigand Pharmaceuticals prices $625M convertible debt offeringJune 23, 2026 | msn.comLigand Announces Pricing of Upsized $625 Million Convertible Senior Notes OfferingJune 23, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 20263 Overlooked Stocks Positioned for the Next Market RotationBy Bridget Bennett | July 13, 2026AFL, LGN, and LGND Company DescriptionsAflac NYSE:AFL$123.26 +1.35 (+1.10%) Closing price 03:59 PM EasternExtended Trading$123.30 +0.05 (+0.04%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan. The Aflac U.S. segment provides cancer, accident, short-term disability, critical illness, hospital indemnity, dental, vision, long-term care and disability, and term and whole life insurance products in the United States. It sells its products through sales associates, brokers, independent corporate agencies, individual agencies, and affiliated corporate agencies. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.LGN NASDAQ:LGN$68.33 -5.33 (-7.24%) Closing price 04:00 PM EasternExtended Trading$68.26 -0.06 (-0.10%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legence Corp. is a provider of engineering, consulting, installation and maintenance services for mission-critical systems in buildings. The company specializes in designing, fabricating and installing complex HVAC, process piping and other mechanical, electrical and plumbing systems. Legence Corp. is based in SAN JOSE, Calif.Ligand Pharmaceuticals NASDAQ:LGND$309.25 -6.99 (-2.21%) Closing price 04:00 PM EasternExtended Trading$310.00 +0.75 (+0.24%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Analysts See Major Upside for These 5 Stocks One Short- and One Long-Term ETF for Quantum Computing Bulls Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
